Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study Meeting Abstract
| Authors: | Pollyea, D. A.; Dinardo, C. D.; de Botton, S.; Stein, E.; Roboz, G. J.; Mims, A. S.; Swords, R. T.; Altman, J. K.; Collins, R.; Mannis, G. N.; Uy, G. L.; Donnellan, W. B.; Pigneux, A.; Fathi, A. T.; Liu, H.; Wu, B.; Attar, E. C.; Tallman, M. S.; Stone, R. M.; Kantarjian, H. M. |
| Abstract Title: | Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 379s |
| Language: | English |
| ACCESSION: | WOS:000442916002499 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.7000 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7000 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work